Clinical Trials | Headline: A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD-19 in Participants with Multiple Myeloma

The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with multiple myeloma for a research study. The purpose of the study is to learn more about whether AZD0120 (a BiSpecific CD119, BCMA CART) is safe to administer to people with newly diagnosed multiple myeloma (MM) and whether AZD0120 can help to treat your type of cancer. AZD0120 is a type of study treatment called Chimeric Antigen Receptor or CAR T-cell therapy. It uses cells from your own immune system, called T-cells, to attack cancer cells. Mature multiple myeloma cancer cells often have a lot of a protein called B-cell maturation antigen (BCMA) that most normal tissues don’t usually have – this makes it a good target for potential cancer treatments. This CART cell has 2 targets both BCMA and another protein call CD19 that is found on immature Myeloma cells. In this study, small groups of people will get different amounts (doses) of AZD0120. Each group will get a different dose than the group before. We will find out the highest safe and tolerable dose of AZD0120. There are multiple parts to the study with exams, tests and/or procedures done at different frequencies. Depending on when you enter the study, you will be in the study for between approximately 2 to 3 years before being asked to switch to the separate long-term follow-up study. Additional information found here: https://clinicaltrials.gov/study/NCT07073547 For questions, contact: [email protected]